Brown Brothers Harriman & Co., a global financial services firm, released its “The BBH Select Series – Mid Cap Fund” first quarter investor letter. A copy of the same can be downloaded here. The fund fell -6.0% in the first quarter on a total return basis, while the Russell Midcap Index decreased -3.4%. The fund generated an average annual total return of 3.1% since its inception on May 24, 2021, compared to the index’s 4.1% return. Given the increased policy uncertainty and market volatility, many of the firm’s management teams issued cautious 2025 guidance. For more information on the fund’s best picks in 2025, please check its top five holdings.
In its first-quarter 2025 investor letter, The BBH Select Series – Mid Cap Fund highlighted stocks such as Bruker Corporation (NASDAQ:BRKR). Bruker Corporation (NASDAQ:BRKR) focuses on the development and manufacturing of scientific instruments and analytical and diagnostic solutions. The one-month return of Bruker Corporation (NASDAQ:BRKR) was 7.28%, and its shares lost 39.26% of their value over the last 52 weeks. On June 24, 2025, Bruker Corporation (NASDAQ:BRKR) stock closed at $39.66 per share, with a market capitalization of $6.01 billion.
The BBH Select Series – Mid Cap Fund stated the following regarding Bruker Corporation (NASDAQ:BRKR) in its Q1 2025 investor letter:
“The Fund’s largest detractors to performance in the quarter were Globant SA.(Globant) and Bruker Corporation (NASDAQ:BRKR). Bruker declined -28.7% during the quarter, ending with a weight of 2.8%. Bruker produces high-performance instruments that enable the exploration of life and materials at a microscopic, molecular, and cellular level. While fourth quarter 2024 results were strong at the high end of guidance, the outlook for 2025 faces challenges from delayed China stimulus and a slow recovery in biopharma. In addition, many of its customers are engaged in early-stage life science research funded by academic and government entities such as the National Institutes of Health, which makes Bruker particularly susceptible to recent government funding cuts at these institutions. However, Bruker is a well-diversified business with a third of its revenues from each of the Americas, EMEA, and Asia-Pacific serving a wide variety of end markets beyond academic and government including industrial, bio pharma, semi-metrology, and diagnostics.”
A scientist in a laboratory wearing safety gear while operating a mass spectrometry machine.
Bruker Corporation (NASDAQ:BRKR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held Bruker Corporation (NASDAQ:BRKR) at the end of the first quarter which was 34 in the previous quarter. Bruker Corporation’s (NASDAQ:BRKR) first quarter revenue increased 11% year-over-year to $801.4 million. While we acknowledge the potential of Bruker Corporation (NASDAQ:BRKR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.
In another article, we covered Bruker Corporation (NASDAQ:BRKR) and shared RGA Investment Advisors’ views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of BRKR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
